Most Popular Stories
- Walgreens plans 100 more retail clinics by mid-2009
- Disruptive doctor behavior causes mistakes, intimidates workers
- AHA survey: Negative profit margins for hospitals
- DOD, VA move to SOA architecture to build interoperable systems
- HHS: 60 percent of DME companies banned by Medicare may keep billing
- Cleveland Clinic lists potential conflicts of interest online
Poll
Featured Jobs
-
Texas Hospitalist
StaffPointe, LLC - south , TX -
Arizona Intensive Care RN
StaffPointe, LLC - north , AZ -
Chief Privacy Officer, Americas Region
IMS Health Incorporated - Plymouth Meeting, PA -
Nevada Internal Medicine
StaffPointe, LLC - Las Vegas , NV -
Maryland OB/GYN CEx1157
StaffPointe, LLC - east , MD
Events
- Avaya Patient Payment Recovery Webinar
Thursday, December 11, 2008 1-2pm
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
- Emerging markets series: Benchmarking key countries Brazil, Russia, India, China and Turkey
Popular Topics
Governors push for cheaper insulin
Diabetes has become one of the most pressing--and expensive--epidemics this country faces. In 2005, state Medicare programs spent a hefty $500 million on the drug insulin to treat diabetes. Given the high price tag, the governors of 11 states are questioning why an inexpensive generic version of insulin is not available. They're approaching the FDA to request that the agency set up an approval process for a generic version of the drug. "To have a lower-cost solution for our very large diabetic population is in the interest of the state and the interest of these people," Mississippi Gov. Haley Barbour (R) told the New York Times.
Insulin has been around for over 80 years, but branded drug makers and generic companies have been fighting over who gets to make it. The issue is that insulin is a biologic, meaning it is a product made from cultures of living materials rather than chemicals. For years branded drug makers have maintained that such products are too complex for generic drug makers to produce, but with the growing expense of treating diabetes, it appears Congress may be ready to allow generic companies to get a piece of the action. If the governors are successful with their campaign, generic insulin products could cost up to 25 percent less than the drug currently available.
For more on the push for generic insulin:
- read this article
Related Articles:
FDA OK's the first generic biologic. Report
Related Stories
- Boston ends Canadian drug import program, citing lack of interest
- Study: Pain doctors rarely sanctioned for narcotic prescriptions
- Eli Lilly to pay $62M to settle Zyprexa marketing charges
- FDA needs to inspect more foreign drugs, GAO finds
- FDA's medical approval process faces GAO scrutiny
- Cost of diabetes care has nearly doubled in six years
- FDA investigated for improper review of medical devices
- Study: Medicaid paid $198 million for unapproved drugs
- FDA contact number may be on DTC ads soon; Critics speak out against New Orleans medical campus;
- ALSO NOTED: High salaries for MA healthcare committee; TV drug commercials don't mention risks; and much more...
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





